Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $24.14, but opened at $25.69. Nanobiotix shares last traded at $26.4850, with a volume of 4,546 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NBTX. Guggenheim started coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Stock Up 10.8%

The firm has a fifty day moving average price of $34.07 and a 200 day moving average price of $36.52.

Nanobiotix Company Profile

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.